SCHEMBL6477867

SCHEMBL6477867

CC1=C2C=C(C(=O)NCc3ccccc3)ON2C(=O)C(Cc2ccc(F)cc2)C1=O

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.41
LMNA P02545 3/20 0.41
KDM4E B2RXH2 1/20 0.41
HPGD P15428 1/20 0.41
CNR2 P34972 1/20 0.41
KMT2A Q03164 3/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2C19 P33261 1/20 0.40
MAPT P10636 2/20 0.40
CACNA1G O43497 1/20 0.39
RAB9A P51151 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
HTT P42858 1/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
TRPA1 O75762 1/20 0.38
MEN1 O00255 2/20 0.38
CXCR4 P61073 1/20 0.38
GAA P10253 1/20 0.38
TSHR P16473 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6822190 0.92 ALDH1A1 (0.36) ALDH1A1LMNAKDM4EHPGDCNR2
SCHEMBL6476937 0.80 SMN1; SMN2 (0.41) ALDH1A1LMNAKDM4EHPGDCNR2
SCHEMBL6288765 0.70 HPGD (0.47) ALDH1A1LMNAKDM4EHPGDCNR2
SCHEMBL6477069 0.70 S1PR3 (0.39) ALDH1A1KDM4EKMT2ACYP1A2CYP2C19
SCHEMBL6292804 0.68 MAPT (0.46) ALDH1A1LMNAKDM4ECNR2KMT2A
SCHEMBL6484455 0.66 PTGER4 (0.38) ALDH1A1KDM4ECYP1A2CYP2C19MAPT
SCHEMBL6488759 0.65 CES2 (0.43) ALDH1A1KDM4EHPGDCYP1A2CYP2C19
SCHEMBL6813863 0.65 L3MBTL1 (0.47) ALDH1A1LMNAL3MBTL1GAA
SCHEMBL6716879 0.64 CNR2 (0.43) ALDH1A1LMNAKDM4EHPGDCNR2
SCHEMBL6477071 0.64 PTGER4 (0.38) ALDH1A1MAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2004014908-A1 HETEROBICYLCIC METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2004-02-19 WO claimed
US-6897223-B2 Pyridine fused bicyclic metalloproteinase inhibitors WARNER-LAMBERT COMPANY (US) 2005-05-24 US disclosed
US-20040039012-A1 Pyridine fused bicyclic metalloproteinase inhibitors WILSON MICHAEL WILLIAM (US) 2004-02-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040039012-A1 Pyridine fused bicyclic metalloproteinase inhibitors MMP9, MMP1, MMP2 ALDH1A1 251/4885LMNA 2417/4885KDM4E 1218/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.